Regeneron expanded its partnership with CytomX Therapeutics by paying $37 million and adding options on conditionally active bispecifics targeting two targets. The expansion increases the deal’s potential value to about $4 billion, reflecting renewed confidence in CytomX’s conditionally activated bispecific approach after prior alliance adjustments. The companies said the added work covers development of new bispecific candidates and secures options on additional programs. Regeneron’s decision comes after the broader alliance landscape saw some pharma partners step away in recent quarters, according to the reporting. For BD and pipeline strategists, the update is a reminder that platform-based oncology partnerships can quickly re-rank priorities as early data and option structures evolve across development cycles.